After a 21.7% year-to-date drop in shares in 2025, Regeneron Pharmaceuticals (REGN) has piqued the interest of various investment management firms, with overall mixed movements in their stock positions. While firms like Acadian Asset Management and AQR Capital Management have significantly increased their holds, others such as Fortis Capital Advisors and Banque Transatlantique have reduced their stakes. Despite setbacks, the FDA has shown confidence in Regeneron's Odronextamab, and the latter has also reported positive Phase 3 results for Myasthenia Gravis trials.
Multiple firms continue to invest or increase their investment in Regeneron, displaying a sense of positive forecast on the firm's future. Meanwhile, Regulatory approvals such as that of Linvoseltamab and positive trial results for Allergen-Blocking Antibodies have added to the firm's recent wins. On the other hand, Regeneron's Eylea injection's review dates have been postponed by the FDA. Finally, not to be overlooked is the firm's.
Regeneron Pharmaceuticals REGN News Analytics from Thu, 08 May 2025 07:00:00 GMT to Sat, 13 Sep 2025 18:37:04 GMT - Rating 5 - Innovation 6 - Information 8 - Rumor -3
